insights_auto
Kwa nini 6160 imeongezeka kwa 4.36%?
Fahamu zaidichevron_right
6160:HKG
BeOne Medicines AG
HK$ 225.00
arrow_upward
+4.36%(+9.40) Siku 1
16 Okt, 16:08:14 GMT +8 · HKD
search
Alama zote
| Alama | Bei | Tofauti | Tofauti ya asilimia |
|---|
insights_autoInatayarisha maarifa maarufu ya 6160...
Fungua
HK$ 224.80
Juu
HK$ 230.20
Chini
HK$ 221.80
Mtaji wa soko
355.76B
Wastani wa kiasi cha mauzo
2.93M
Kiasi cha mauzo ya hisa
4.41M
Uwiano wa bei ya hisa na mapato kwa kila hisa
65.67
Juu kwa wiki 52
HK$ 235.60
Chini kwa wiki 52
HK$ 153.00
EPS
HK$ 3.43
Hisa za wawekezaji
1.43B
Idadi ya wafanyakazi
elfu 12
Fungua
HK$ 224.80
Juu
HK$ 230.20
Chini
HK$ 221.80
Mtaji wa soko
355.76B
Wastani wa kiasi cha mauzo
2.93M
Kiasi cha mauzo ya hisa
4.41M
Uwiano wa bei ya hisa na mapato kwa kila hisa
65.67
Juu kwa wiki 52
HK$ 235.60
Chini kwa wiki 52
HK$ 153.00
EPS
HK$ 3.43
Hisa za wawekezaji
1.43B
Idadi ya wafanyakazi
elfu 12
Habari
Kutoka kwenye vyanzo vya wavuti na washirika wa habari
MarketBeat
·
siku 3 zilizopita
BeOne Medicines (NASDAQ:ONC) Stock: Insider Xiaodong Wang Sells 31,027 Shares
Wasifu
BeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment.
Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
BeOne Medicines has developed several medicines, including tislelizumab, a checkpoint inhibitor, and zanubrutinib, a Bruton's tyrosine kinase inhibitor. On 14 November 2024, the company announced its intention to rebrand as BeOne Medicines. BeOne changed its stock ticker to ONC in January 2025 and redomiciled to Basel, Switzerland in May 2025. Wikipedia
Kuhusu BeOne Medicines AG
Afisa Mkuu Mtendaji (CEO)John Vincent Oyler | John Vincent Oyler
Wafanyakazielfu 12
Lilianzishwa28 Okt 2010
Makao makuu-
Sekta-
Tovutibeonemedicines.com